Our new website is LIVE!

Redesigned website reflects the company’s broader approach to physiological upregulation, and laser focus on neurodegenerative disease targets

Leveraging its core expertise in RNA biology/bioinformatics and neuro cell biology, Harness is developing a pipeline of next generation treatments for neurodegenerative diseases.

“Delighted to be launching our new website ready for engaging investors and partners in 2024. We look forward to sharing further information about our plans in Huntington's disease; and also, before long, our 2nd programme targeting another important neurodegenerative disease” said Jan Thirkettle, CEO of Harness Therapeutics.

Our vision

Building the leading platform for physiological upregulation of neurodegenerative disease targets to enable truly disease-modifying therapies.

Our approach

Deep expertise & unique capabilities in RNA biology & neurodegeneration

High value targets

Ready to scale

Learn more

Our programmes

Preventing the progression of Huntingtonā€™s Disease

Discover more

Our news

View all